On May 8, 2026, InxMed Biotechnology (Nanjing) Co., Ltd. announced a strategic partnership with Fosun Pharma. Under the agreement, InxMed Bio will grant Fosun Pharma the exclusive rights for sales, promotion, and full-channel commercialization of its two self-developed innovative FAK inhibitors, IN10018 (Ifebemtinib) and IN10028, in mainland China (excluding Hong Kong, Macau, and Taiwan).

As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance.
As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance.
IN10018 is an innovative small-molecule FAK inhibitor with dual regulatory functions — kinase catalytic and protein scaffold — that exerts anti-tumor effects through multiple mechanisms including oncogenic pathway modulation and inhibition of tumor proliferation and invasion. The product has received three Breakthrough Therapy Designations from the NMPA and one Fast Track Designation from the U.S. FDA. IN10018 is currently in Phase III clinical trials in China.
IN10028 is InxMed Bio's self-developed second-generation FAK inhibitor. While retaining the excellent anti-tumor activity of the first generation, it achieves further optimization in pharmacokinetic properties and safety profile, broadening the target patient population. The drug has received IND approval from the NMPA and will soon initiate Phase I clinical studies.

Founded in 2017, InxMed Bio's core pipeline is IN10018, which is expected to file for marketing approval in the second half of this year, nearing the commercialization stage. Follow-up pipelines include IN10028, FAP ADC, integrin α3β1 ADC, and a PD-1/GDF15 bispecific antibody. On April 21, 2026, InxMed Bio re-submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities and CCB International as joint sponsors.